In inadequately controlled patients with Type 2 diabetes, Biphasic Insulin Aspart 30 combined with Pioglitazone provides better glycaemic control than Biphasic Insulin Aspart 30 monotherapy or Pioglitazone/Sulphonylurea combination.

被引：0
|
作者：
Raz, I
Stranks, S
Filipczak, R
Joshi, P
Lertoft, B
Råstam, J
Chow, FC
机构：
[1] Hadassah Hebrew Univ Hosp, Diabet Unit, Jerusalem, Israel
[2] Repatriat Gen Hosp, Daw Pk, Australia
[3] NZOZ Gadent, Diabet Unit, Rawa Mazowiecka, Poland
[4] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark
[5] Prince Wales Hosp, Diabet & Endocrine Ctr, Shatin, Hong Kong, Peoples R China
来源：
DIABETOLOGIA | 2003年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15
引用
收藏
页码：A8 / A8
页数：1
相关论文
共 50 条
  • [21] COST EFFECTIVENESS ANALYSIS OF SWITCHING PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES TO BIPHASIC INSULIN ASPART 30 FROM BIPHASIC HUMAN INSULIN 30 IN THE CZECH SETTING
    Suchankova, E.
    Dolezal, T.
    Pisarikova, Z.
    Rychna, K.
    Bartaskova, D.
    VALUE IN HEALTH, 2009, 12 (07) : A405 - A406
  • [22] Once daily initiation with biphasic insulin aspart 30 (BIAsp 30) versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs - a randomized controlled trial
    Franek, E.
    Kalra, S.
    Pesic, M.
    Smahelova, A.
    Thomsen, H.
    Strojek, K.
    DIABETOLOGIA, 2009, 52 : S93 - S93
  • [23] Efficacy and Safety of Insulin Degludec/Insulin Aspart versus Biphasic Insulin Aspart 30 in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
    Niu, Yan-Li
    Zhang, Ye
    Song, Zhi-Yong
    Zhao, Chuan-Zhi
    Luo, Yun
    Wang, Yan
    Yuan, Jing
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2024, 53 (02) : 313 - 322
  • [24] Thrice-daily injections of biphasic insulin aspart 30 (NovoMix® 70/30) improves glycaemic control in patients with type 1 diabetes
    Chen, JW
    Lauritzen, T
    Bojesen, A
    Christiansen, J
    DIABETOLOGIA, 2005, 48 : A330 - A330
  • [25] Effect of biphasic insulin aspart 30/70 (BIAsp30) in combination with metformin on glycaemic control in subjects with type 2 diabetes not optimally controlled on oral antidiabetic agents
    Naiker, P.
    Makan, H. A.
    Omar, M. A. K.
    Kedijang, T.
    Kong, L. L. L.
    DIABETOLOGIA, 2006, 49 : 599 - 600
  • [26] Efficacy of biphasic insulin aspart in patients with type 2 diabetes
    Halimi, S
    Raskin, P
    Liebl, A
    Kawamori, R
    Fulcher, G
    Yan, G
    CLINICAL THERAPEUTICS, 2005, 27 : S57 - S74
  • [27] A comparison of pharmocodynamics and pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 & Pure Insulin Aspart in type 1 diabetes
    Thorisdottir, Rannveig L.
    Parkner, Tina
    Chen, Jian-Wen
    Ejskjaer, Niels
    Christiansen, Jens S.
    DIABETES, 2007, 56 : A555 - A555
  • [28] Treatment with biphasic insulin aspart 30 improves glycaemic control in patients with Type 2 diabetes inadequately controlled with oral antidiabetic drugs: results from China cohort in the PRESENT study
    Gao, Yan
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 79 : S64 - S65
  • [29] Effect of BIAsp 30 (biphasic insulin aspart 30) in combination with oral hypoglycaemic agents on glycaemic regulation in non-obese patients with type 2 diabetes
    Lund, S. S.
    Tarnow, L.
    Nielsen, B. B.
    Hansen, B. V.
    Pedersen, O.
    Parving, H. -H.
    Vaag, A. A.
    DIABETOLOGIA, 2006, 49 : 600 - 600
  • [30] Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts)
    Raskin, P.
    Matfin, G.
    Schwartz, S. L.
    Chaykin, L.
    Chu, P. -L.
    Braceras, R.
    Wynne, A.
    DIABETES OBESITY & METABOLISM, 2009, 11 (01): : 27 - 32
12345